Our research findings indicate that genetic deletion or pharmacological inhibition of RBMS1 expression can alleviate cardiac hypertrophy, thereby confirming that RBMS1 is a promising therapeutic target for the treatment of cardiac hypertrophy and heart failure. This evidence concerns the gene RBMS1 and heart failure.